Comparison · NCT02769481-sae
Bexagliflozin vs Glimepiride: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Bexagliflozin vs Glimepiride: serious adverse events. Trial comparisons, record NCT02769481-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02769481-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.117 | 0.0808 | 0.168 | wilson | |
| Risk in group 2 | 0.122 | 0.0847 | 0.173 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00469 | -0.0673 | 0.0579 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.962 | 0.574 | 1.61 | log | |
| Odds ratio, group 1 over group 2 | 0.956 | 0.533 | 1.72 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Bexagliflozin than on Glimepiride | 213 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Bexagliflozin | Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride for the duration of the study.~Bexagliflozin tablets: 20 mg~Glimepiride capsules: Placebo, inactive capsule to match the active comparator | 25 | 213 | EG000 |
| Group 2 | Glimepiride | Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.~Bexagliflozin: Placebo, inactive tablet to match the active comparator~Glimepiride capsules: 2, 4 or 6 mg | 26 | 213 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse event data was collected from Week -8 (V2, wash-out) to Week 98 (V18, follow-up).
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
- NCT number
- NCT02769481
- Phases
- PHASE3
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Bexagliflozin, Placebo for Bexagliflozin, Glimepiride, Placebo for Glimepiride
- Lead sponsor
- Theracos
- Results first posted
- 2021-05-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02769481?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02769481-sae